Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

5.970 +0.170 (+2.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,126,128
Open 6.060
Bid (Size) 5.780 (10)
Ask (Size) 6.250 (8)
Prev. Close 5.800
Today's Range 5.930 - 6.220
52wk Range 4.950 - 14.45
Shares Outstanding 133,976,538
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
5 Analysts Have This To Say About Vir Biotechnology
Via Benzinga
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire

Performance

YTD
-17.9%
-17.9%
1 Month
-17.1%
-17.1%
3 Month
-43.3%
-43.3%
6 Month
-20.6%
-20.6%
1 Year
-26.6%
-26.6%

More News

Read More
7 Analysts Have This To Say About Vir Biotechnology
Via Benzinga
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Earnings Scheduled For February 26, 2025
Via Benzinga
Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment
Via Investor's Business Daily
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
From Vir Biotechnology, Inc.
Via Business Wire
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why
Via Benzinga
AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
AT&T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients
Via Investor's Business Daily
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
From Vir Biotechnology, Inc.
Via Business Wire
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?
Via Benzinga
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
From Vir Biotechnology, Inc.
Via Business Wire

Frequently Asked Questions

Is Vir Biotechnology, Inc. - Common Stock publicly traded?
Yes, Vir Biotechnology, Inc. - Common Stock is publicly traded.
What exchange does Vir Biotechnology, Inc. - Common Stock trade on?
Vir Biotechnology, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vir Biotechnology, Inc. - Common Stock?
The ticker symbol for Vir Biotechnology, Inc. - Common Stock is VIR on the Nasdaq Stock Market
What is the current price of Vir Biotechnology, Inc. - Common Stock?
The current price of Vir Biotechnology, Inc. - Common Stock is 5.970
When was Vir Biotechnology, Inc. - Common Stock last traded?
The last trade of Vir Biotechnology, Inc. - Common Stock was at 04/23/25 04:00 PM ET
What is the market capitalization of Vir Biotechnology, Inc. - Common Stock?
The market capitalization of Vir Biotechnology, Inc. - Common Stock is 799.84M
How many shares of Vir Biotechnology, Inc. - Common Stock are outstanding?
Vir Biotechnology, Inc. - Common Stock has 800M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback